Literature DB >> 24638926

In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Erming Tian1, Jeffrey R Sawyer, Christoph J Heuck, Qing Zhang, Frits van Rhee, Bart Barlogie, Joshua Epstein.   

Abstract

In studies of patients with multiple myeloma (MM), gene expression profiling (GEP) of myeloma cells demonstrates substantially higher expression of MMSET, FGFR3, CCND3, CCND1, MAF, and MAFB--the partner genes of 14q32 translocations--than GEP of plasma cells from healthy individuals. Interphase fluorescent in situ hybridization (FISH) was used to discriminate between chromosomal translocations involving different regions of the immunoglobulin heavy chain (IGH) genes at 14q32. With special probes designed for the constant region (IGHC) and the variable region (IGHV), IGH translocations were shown to be definite, nonrandom chromosomal fusions of IGHC with the loci of FGFR3, CCND1, CCND3, MAF, and MAFB genes; and IGHV with the locus of MMSET gene. When correlated with GEP results, the IGH translocations were found to drive expression levels of the partner genes to significantly higher levels (spikes) than copy-number variations. Hence, 42% of IGH translocations were identified among newly diagnosed MM patients (448/1,060). As GEP has become essential for assessing cancer risk, this novel approach is highly consistent with the cytogenetic features of the chromosomal translocations to effectively stratify molecular subgroups of MM on the basis of gene expression profiles of the IGH translocation partner genes in myeloma cells. © 2014 Wiley Periodicals, Inc.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24638926      PMCID: PMC4016160          DOI: 10.1002/gcc.22165

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  30 in total

1.  Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling.

Authors:  Richard Simon
Journal:  J Natl Cancer Inst       Date:  2006-09-06       Impact factor: 13.506

2.  Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.

Authors:  G Tricot; J R Sawyer; S Jagannath; K R Desikan; D Siegel; S Naucke; S Mattox; D Bracy; N Munshi; B Barlogie
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

3.  Plasma cell karyotype in multiple myeloma.

Authors:  J Gould; R Alexanian; A Goodacre; S Pathak; B Hecht; B Barlogie
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

4.  Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.

Authors:  Friedrich W Cremer; Jelena Bila; Isabelle Buck; Mutlu Kartal; Dirk Hose; Carina Ittrich; Axel Benner; Marc S Raab; Ann-Cathrin Theil; Marion Moos; Hartmut Goldschmidt; Claus R Bartram; Anna Jauch
Journal:  Genes Chromosomes Cancer       Date:  2005-10       Impact factor: 5.006

Review 5.  Chromosome translocations in multiple myeloma.

Authors:  P L Bergsagel; W M Kuehl
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

6.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.

Authors:  M Chesi; P L Bergsagel; O O Shonukan; M L Martelli; L A Brents; T Chen; E Schröck; T Ried; W M Kuehl
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

7.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Authors:  M Chesi; E Nardini; R S Lim; K D Smith; W M Kuehl; P L Bergsagel
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

Review 8.  Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.

Authors:  J L Laï; M Zandecki; J Y Mary; F Bernardi; V Izydorczyk; M Flactif; P Morel; J P Jouet; F Bauters; T Facon
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

9.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.

Authors:  G Tricot; B Barlogie; S Jagannath; D Bracy; S Mattox; D H Vesole; S Naucke; J R Sawyer
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  11 in total

1.  MicroRNA-154 inhibits growth and invasion of breast cancer cells through targeting E2F5.

Authors:  Hui Xu; Dan Fei; Shan Zong; Zhimin Fan
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.

Authors:  David Martín-Garcia; Alba Navarro; Rafael Valdés-Mas; Guillem Clot; Jesús Gutiérrez-Abril; Miriam Prieto; Inmaculada Ribera-Cortada; Renata Woroniecka; Grzegorz Rymkiewicz; Susanne Bens; Laurence de Leval; Andreas Rosenwald; Judith A Ferry; Eric D Hsi; Kai Fu; Jan Delabie; Dennis Weisenburger; Daphne de Jong; Fina Climent; Sheila J O'Connor; Steven H Swerdlow; David Torrents; Sergi Beltran; Blanca Espinet; Blanca González-Farré; Luis Veloza; Dolors Costa; Estella Matutes; Reiner Siebert; German Ott; Leticia Quintanilla-Martinez; Elaine S Jaffe; Carlos López-Otín; Itziar Salaverria; Xose S Puente; Elias Campo; Sílvia Beà
Journal:  Blood       Date:  2018-12-11       Impact factor: 22.113

3.  Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesis.

Authors:  Xiaoqing Cheng; Yuan Hao; Wenjie Shu; Mengjie Zhao; Chen Zhao; Yuan Wu; Xiaodan Peng; Pinfang Yao; Daibiao Xiao; Guoliang Qing; Zhengying Pan; Lei Yin; Desheng Hu; Hai-Ning Du
Journal:  J Biol Chem       Date:  2017-04-25       Impact factor: 5.157

4.  Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Authors:  J R Sawyer; E Tian; J D Shaughnessy; J Epstein; C M Swanson; C Stangeby; C L Hale; L Parr; M Lynn; G Sammartino; J L Lukacs; C Stein; C Bailey; M Zangari; F E Davies; F Van Rhee; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

5.  MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32).

Authors:  Nicoletta Coccaro; Giuseppina Tota; Luisa Anelli; Antonella Zagaria; Paola Casieri; Angelo Cellamare; Crescenzio Francesco Minervini; Angela Minervini; Cosimo Cumbo; Luciana Impera; Claudia Brunetti; Paola Orsini; Elisa Parciante; Anna Mestice; Giorgina Specchia; Francesco Albano
Journal:  Oncol Lett       Date:  2016-06-22       Impact factor: 2.967

6.  Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.

Authors:  Erming Tian; Magne Børset; Jeffrey R Sawyer; Gaute Brede; Thea K Våtsveen; Håkon Hov; Anders Waage; Bart Barlogie; John D Shaughnessy; Joshua Epstein; Anders Sundan
Journal:  Genes Chromosomes Cancer       Date:  2015-07-29       Impact factor: 5.006

7.  Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma.

Authors:  S W Erickson; O W Stephens; S S Chavan; E Tian; J Epstein; B Barlogie; C J Heuck; A J Vangsted
Journal:  Leukemia       Date:  2015-08-26       Impact factor: 11.528

Review 8.  The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers.

Authors:  Zbyslaw Sondka; Sally Bamford; Charlotte G Cole; Sari A Ward; Ian Dunham; Simon A Forbes
Journal:  Nat Rev Cancer       Date:  2018-11       Impact factor: 60.716

9.  Expressed fusion gene landscape and its impact in multiple myeloma.

Authors:  A Cleynen; R Szalat; M Kemal Samur; S Robiou du Pont; L Buisson; E Boyle; M L Chretien; K Anderson; S Minvielle; P Moreau; M Attal; G Parmigiani; J Corre; N Munshi; H Avet-Loiseau
Journal:  Nat Commun       Date:  2017-12-01       Impact factor: 14.919

10.  Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia.

Authors:  Shebli Atrash; Qing Zhang; Xenofon Papanikolaou; Caleb Stein; Al-Ola Abdallah; Bart Barlogie
Journal:  J Glob Oncol       Date:  2017-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.